Cargando…

A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)

Real-world data on the effectiveness of COVID-19 vaccines against the Omicron variant (B.1.1.529) is limited. This systematic review aimed to investigate the real-world effectiveness and durability of protection conferred by primary course and booster vaccines against confirmed Omicron infection, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammed, Hassen, Pham-Tran, Dan Duy, Yeoh, Zi Yi Michelle, Wang, Bing, McMillan, Mark, Andraweera, Prabha H., Marshall, Helen S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965204/
https://www.ncbi.nlm.nih.gov/pubmed/36851102
http://dx.doi.org/10.3390/vaccines11020224
_version_ 1784896699610693632
author Mohammed, Hassen
Pham-Tran, Dan Duy
Yeoh, Zi Yi Michelle
Wang, Bing
McMillan, Mark
Andraweera, Prabha H.
Marshall, Helen S.
author_facet Mohammed, Hassen
Pham-Tran, Dan Duy
Yeoh, Zi Yi Michelle
Wang, Bing
McMillan, Mark
Andraweera, Prabha H.
Marshall, Helen S.
author_sort Mohammed, Hassen
collection PubMed
description Real-world data on the effectiveness of COVID-19 vaccines against the Omicron variant (B.1.1.529) is limited. This systematic review aimed to investigate the real-world effectiveness and durability of protection conferred by primary course and booster vaccines against confirmed Omicron infection, and severe outcomes. We systematically searched literature up to 1 August 2022. Meta-analysis was performed with the DerSimonian-Laird random-effects model to estimate the pooled vaccine effectiveness (VE). Overall, 28 studies were included representing 11 million individuals. The pooled VE against Omicron infection was 20.4% (95%CI: 12.1–28.7%) and 23.4% (95%CI: 13.5–33.3%) against symptomatic infection with variation based on vaccine type and age groups. VE sharply declined from 28.1% (95%CI: 19.1–37.1%) at three months to 3.9% (95%CI: −24.8–32.7%) at six months. Similar trends were observed for symptomatic Omicron infection. A booster dose restored protection against Omicron infection up to 51.1% (95%CI: 43.8–58.3%) and 57.3% (95%CI: 54.0–60.5%) against symptomatic infection within three months; however, this waned to 32.8% (95%CI: 16.8–48.7%) within six months. VE against severe Omicron infection following the primary course was 63.6% (95%CI: 57.5–69.7%) at three months, decreased to 49% (95%CI: 35.7–63.4%) within six months, and increased to 86% after the first or second booster dose.
format Online
Article
Text
id pubmed-9965204
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99652042023-02-26 A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529) Mohammed, Hassen Pham-Tran, Dan Duy Yeoh, Zi Yi Michelle Wang, Bing McMillan, Mark Andraweera, Prabha H. Marshall, Helen S. Vaccines (Basel) Systematic Review Real-world data on the effectiveness of COVID-19 vaccines against the Omicron variant (B.1.1.529) is limited. This systematic review aimed to investigate the real-world effectiveness and durability of protection conferred by primary course and booster vaccines against confirmed Omicron infection, and severe outcomes. We systematically searched literature up to 1 August 2022. Meta-analysis was performed with the DerSimonian-Laird random-effects model to estimate the pooled vaccine effectiveness (VE). Overall, 28 studies were included representing 11 million individuals. The pooled VE against Omicron infection was 20.4% (95%CI: 12.1–28.7%) and 23.4% (95%CI: 13.5–33.3%) against symptomatic infection with variation based on vaccine type and age groups. VE sharply declined from 28.1% (95%CI: 19.1–37.1%) at three months to 3.9% (95%CI: −24.8–32.7%) at six months. Similar trends were observed for symptomatic Omicron infection. A booster dose restored protection against Omicron infection up to 51.1% (95%CI: 43.8–58.3%) and 57.3% (95%CI: 54.0–60.5%) against symptomatic infection within three months; however, this waned to 32.8% (95%CI: 16.8–48.7%) within six months. VE against severe Omicron infection following the primary course was 63.6% (95%CI: 57.5–69.7%) at three months, decreased to 49% (95%CI: 35.7–63.4%) within six months, and increased to 86% after the first or second booster dose. MDPI 2023-01-19 /pmc/articles/PMC9965204/ /pubmed/36851102 http://dx.doi.org/10.3390/vaccines11020224 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Mohammed, Hassen
Pham-Tran, Dan Duy
Yeoh, Zi Yi Michelle
Wang, Bing
McMillan, Mark
Andraweera, Prabha H.
Marshall, Helen S.
A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)
title A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)
title_full A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)
title_fullStr A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)
title_full_unstemmed A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)
title_short A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)
title_sort systematic review and meta-analysis on the real-world effectiveness of covid-19 vaccines against infection, symptomatic and severe covid-19 disease caused by the omicron variant (b.1.1.529)
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965204/
https://www.ncbi.nlm.nih.gov/pubmed/36851102
http://dx.doi.org/10.3390/vaccines11020224
work_keys_str_mv AT mohammedhassen asystematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529
AT phamtrandanduy asystematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529
AT yeohziyimichelle asystematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529
AT wangbing asystematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529
AT mcmillanmark asystematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529
AT andraweeraprabhah asystematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529
AT marshallhelens asystematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529
AT mohammedhassen systematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529
AT phamtrandanduy systematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529
AT yeohziyimichelle systematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529
AT wangbing systematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529
AT mcmillanmark systematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529
AT andraweeraprabhah systematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529
AT marshallhelens systematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529